Niacin--a case study for the role of event-driven versus surrogate endpoint trials

Heart. 2013 Nov;99(22):1631-2. doi: 10.1136/heartjnl-2013-304545. Epub 2013 Sep 16.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Biomarkers
  • Clinical Trials as Topic / standards*
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Niacin / therapeutic use*

Substances

  • Biomarkers
  • Hypolipidemic Agents
  • Niacin